Clinical Trial Update: The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the impact of an SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease in adults with type 2 diabetes; the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Sohag University | Conditions: Fatty Liver, Nonalcoholic | Phase 3 | Status: COMPLETED